Serum Institute of India to apply for emergency authorisation of COVID-19 vaccine in next two weeks
Nov 29, 2020 |
, |
8:37AM |
Serum Institute of India to apply for emergency authorisation of COVID-19 vaccine in next two weeks
Mr Poonawalla said Covishield is a highly effective vaccine against novel coronavirus. AstraZeneca and Oxford University earlier said that their drug had proved on average 70% effective at stopping the virus after trying it on 23,000 people.
Mr Poonawalla said, India will be given first priority for the delivery of the AstraZeneca-Oxford vaccine. He said, the COVID-19 vaccine will be distributed initially in India, then we will look at the COVAX countries which are mainly in Africa. He said our priority is India & COVAX countries, while the United Kingdom and European markets are being taken care of by AstraZeneca and Oxford.